Future Of Cardio And Mental Health Will Be Defined By Digital Advances

Cardiovascular diseases are responsible for 30% of worldwide deaths, and about 25% of the global population experiences mental illness each year. The negative impact of these conditions on society remain substantial. Development of digital tools to provide support to high-risk groups and patients, healthcare providers, and communities in general, is an area of significant opportunity.

IV1812_Body Analysis_657922240 _1200.jpg
Exploring digital innovation in heart and mental health • Source: Shutterstock

Health care for a long time has relied on the traditional treatment-based, physician-centric approach, which is strained by increasing demand and resource constraints. This applies to many chronic diseases including cardiovascular diseases and mental illnesses. However, these approaches are no longer enough to tackle the long-term health crisis and there is dire need for effective preventive strategies and long-term, cost-effective, sustainable solutions. Digital health tools are one such solution, which is cost-effective and has a capacity to reach a great number of patients and affect them.

There is strong evidence that digital health technology adopting behavioral interventions can significantly reduce the burden of many chronic conditions. Moreover, most chronic diseases are inter-linked and managing one condition can benefit or decrease the risk of other related conditions. The health care sector is moving toward a very interesting time in digital health where there is a lot of opportunity to address significant health problems

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Drug Pricing

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Soriot Cautions Europe Amid More US Expansion

 
• By 

The AstraZeneca CEO again calls for rich European countries to pay more for new drugs because "a model where the US funds innovation in our industry for the entire world doesn't work."

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By 

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

More from Scrip

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By 

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.